CARsgen Therapeutics (HKG:2171) expects its H1 loss to narrow year over year, according to a Hong Kong bourse filing Friday.
The cell therapies producer said it expects a loss of up to 80 million yuan for the six months ended June 30, as compared with a loss of 351 million yuan in the year-ago period.
CARsgen expects to report its financial results by the end of August.
Shares of the company were up over 1% in morning trade Friday.